Res Nova Biologics

Res Nova Biologics is a clinical‑stage oncology company developing non‑toxic cancer immunotherapies. Lead small‑molecule combination FloraStilbene (mifepristone + pterostilbene) has moved from preclinical studies showing immune stimulation and synergy with checkpoint inhibitors, CAR‑T therapies, and chemotherapy in triple negative breast cancer models into early clinical/right‑to‑try use in advanced cancer and metastatic breast cancer patients, with initial compassionate‑use treatments reported but no controlled efficacy data yet. The company also develops ValloVax, an anti‑angiogenic cancer blood‑vessel vaccine, and StemVacs‑V, an induced pluripotent stem cell–derived cancer endothelial vaccine, reported as progressing toward or into Phase II in metastatic breast cancer.